Takeaway
- Real-world data demonstrate clinically significant glucose-lowering with the once-weekly subcutaneous human glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide in adults with type 2 diabetes for up to 720 days in both GLP-1RA experienced and naive people.
- Approximately 1 of 4 patients discontinued treatment during the first 6 months.
Why this...